Title : The FDA-Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola Virus.

Pub. Date : 2019 Sep 27

PMID : 31402258






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 We find that NTZ enhances retinoic-acid-inducible protein I (RIG-I)-like-receptor, mitochondrial antiviral signaling protein, interferon regulatory factor 3, and interferon activities and induces transcription of the antiviral phosphatase GADD34. nitazoxanide DExD/H-box helicase 58 Homo sapiens
2 NTZ significantly inhibits EBOV replication in human cells through its effects on RIG-I and protein kinase R (PKR), suggesting that it counteracts EBOV VP35 protein"s ability to block RIG-I and PKR sensing of EBOV. nitazoxanide DExD/H-box helicase 58 Homo sapiens
3 NTZ significantly inhibits EBOV replication in human cells through its effects on RIG-I and protein kinase R (PKR), suggesting that it counteracts EBOV VP35 protein"s ability to block RIG-I and PKR sensing of EBOV. nitazoxanide DExD/H-box helicase 58 Homo sapiens
4 NTZ also inhibits a second negative-strand RNA virus, vesicular stomatitis virus (VSV), through RIG-I and GADD34, but not PKR, consistent with VSV"s distinct host innate immune evasion mechanisms. nitazoxanide DExD/H-box helicase 58 Homo sapiens